# Kraig Biocraft Laboratories, Inc.: Form 10-Q for the period ended Jun 30, 2019

- Company: [Kraig Biocraft Laboratories, Inc.](/companies/kblb.md) (CIK 1413119)
- Form: 10-Q
- Filed: 2019-08-12
- Accepted by EDGAR: Aug 12, 2019, 17:17 ET
- Period: 2019-06-30
- Accession: 0001654954-19-009271
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1413119/000165495419009271/KBLB_Q22019.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1413119/000165495419009271/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-04-01 to 2019-06-30 | $0 | us-gaap:Revenues |
| Revenue | 6 months, 2019-01-01 to 2019-06-30 | $0 | us-gaap:Revenues |
| Research and development | 3 months, 2019-04-01 to 2019-06-30 | $20.9k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2019-01-01 to 2019-06-30 | $43.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-04-01 to 2019-06-30 | −$335.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2019-01-01 to 2019-06-30 | −$747.3k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-04-01 to 2019-06-30 | $70.7k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2019-01-01 to 2019-06-30 | $137.6k | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-04-01 to 2019-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2019-01-01 to 2019-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-04-01 to 2019-06-30 | −$402.5k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2019-01-01 to 2019-06-30 | −$880.2k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-04-01 to 2019-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2019-01-01 to 2019-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2019-01-01 to 2019-06-30 | −$455.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2019-01-01 to 2019-06-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-06-30 | $674.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-06-30 | $709.5k | us-gaap:AssetsCurrent |
| Total assets | at 2019-06-30 | $1.3m | us-gaap:Assets |
| Current liabilities | at 2019-06-30 | $4.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-06-30 | $5.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-06-30 | −$4.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 30,830 characters.

### FORWARD-LOOKING INFORMATION

The following information should be read in conjunction with Kraig Biocraft Laboratories, Inc. and its subsidiaries ("we", "us", "our", or the “Company”) condensed unaudited financial statements and the notes thereto contained elsewhere in this report. Information in this Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in this Form 10-Q that does not consist of historical facts, are "forward-looking statements." Statements accompanied or qualified by, or containing words such as "may," "will," "should," "believes," "expects," "intends," "plans," "projects," "estimates," "predicts," "potential," "outlook," "forecast," "anticipates," "presume," and "assume" constitute forward-looking statements, and as such, are not a guarantee of future performance.

Forward-looking statements are subject to risks and uncertainties, certain of which are beyond our control. Actual results could differ materially from those anticipated as a result of the factors described in the “Risk Factors” and detailed in our other Securities and Exchange Commission (“SEC”) filings. Risks and uncertainties can include, among others, international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to obtain sufficient financing to continue and expand business operations; the ability to develop technology and products; changes in technology and the development of technology and intellectual property by competitors; the ability to protect technology and develop intellectual property; and other factors referenced in this and previous filings. Consequently, investors should not place undue reliance on forward-looking statements as predictive of future results.

Because of these risks and uncertainties, the forward-looking events and circumstances discussed in this report or incorporated by reference might not transpire. Factors that cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described elsewhere in this report and in the “Risk Factors” section of our registration statement on Form S-1.

The Company disclaims any obligation to update the forward-looking statements in this report.

### Overview

Kraig Biocraft Laboratories, Inc. is a corporation organized under the laws of Wyoming on April 25, 2006. We were organized to develop high strength fibers using recombinant DNA technology, for commercial applications in both the specialty fiber and technical textile industries. Specialty fibers are engineered for specific uses that require exceptional strength, flexibility, heat resistance and/or chemical resistance. The specialty fiber market is exemplified by two synthetic fiber products: aramid fibers and ultra-high molecular weight polyethylene fiber. The technical textile industry involves products for both industrial and consumer products, such as filtration fabrics, medical textiles (e.g., sutures and artificial ligaments), safety and protective clothing and fabrics used in military and aerospace applications (e.g., high-strength composite materials).

We are using genetic engineering technologies to develop fibers with greater strength, resiliency and flexibility for use in our target markets, namely the textile, specialty fiber and technical textile industries.

The Report of Independent Registered Public Accounting Firm to our financial statements as of December 31, 2018 include an explanatory paragraph stating that our net loss from operations and net capital deficiency at December 31, 2018 raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

### Plan of Operations

During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:

- We plan to accelerate both our microbiology and selective breeding programs as well as providing more resources for our material testing protocols into 2019. We spent approximately $148,069 during the year ended December 31, 2018 on research and development of high strength polymers. In 2018 we directed our research and development efforts on growing our internal capabilities. We will consider renewing funding of the collaborative research and development of high strength polymers at the University of Notre Dame in 2019.
- We expect to spend approximately $13,700 on collaborative research and development of high strength polymers and spider silk protein at the University of Wyoming over the next twelve months. This level of research spending at the university is also a requirement of our licensing agreement with the university.
- We plan to complete renovations of our Quang Nam, Vietnam factory and begin commercial scale production of our recombinant spider silk in Vietnam according to our investment and enterprise registration certificates.
- We will consider buying an established revenue producing company in a compatible business, in order to broaden our financial base and facilitate the commercialization of our products. We expect to use a combination of stock and cash for any such purchase.
- We will also actively consider pursuing collaborative research opportunities with both private and university laboratories in areas of research which overlap the company’s existing research and development. One such potential area for collaborative research which the company is considering is protein expression platforms. If our financing allows, management will give strong consideration to increasing the breadth of our research to include protein expression platform technologies.
- We plan to actively pursue collaborative research and product testing, opportunities with companies in the biotechnology, materials, textile and other industries.
- We plan to actively pursue collaborative commercialization, marketing and manufacturing opportunities with companies in the textile and material sectors for the fibers we developed and for any new polymers that we create in 2019.
- We plan to actively pursue the development of commercial scale production of our recombinant materials including Monster Silk® and Dragon SilkTM.

### Limited Operating History

We have not previously demonstrated that we will be able to expand our business through an increased investment in our research and development efforts. We cannot guarantee that the research and development efforts described in this filing will be successful. Our business is subject to risks inherent in growing an enterprise, including limited capital resources, risks inherent in the research and development process and possible rejection of our products in development.

If financing is not available on satisfactory terms, we may be unable to continue our research and development and other operations. Equity financing will result in dilution to existing shareholders.

Three months ended June 30, 2019 compared to the three Months Ended June 30, 2018

Our revenue, operating expenses, and net loss from operations for the three month period ended June 30, 2019 as compared to the three month period ended June 30, 2018, were as follows – some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:

|  | Three Months Ended June 30, 2019 Increase (Decrease) 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| NET REVENUES | $- | $152,230 | (152,230) | -100.00% |
| OPERATING EXPENSES: |  |  |  |  |
| General and Administrative | 122,186 | 99,294 | 22,982 | 23.05% |
| Professional Fees | 37,917 | 30,326 | 7,591 | 25.03% |
| Officer's Salary | 148,050 | 121,762 | 26,288 | 21.59% |
| Rent - Related Party | 6,153 | 2,880 | 3,273 | 113.65% |
| Research and Development | 20,937 | 50,894 | (29,957) | -58.86% |
| Total operating expenses | 335,243 | 305,156 | 30,087 | 9.86% |
| Loss from operations | (335,243) | (152,926) | (182,317) | 119.22% |
| Gain on forgiveness of debt | - | 19,924 | (19,924) | 100.00% |
| Interest expense | (70,695) | (55,588) | (15,107) | 27.18% |
| Interest income | 3,442 | - | 3,442 | 100.00% |
| Net Loss | $(402,497) | $(188,590) | (213,907) | 113.42% |

Net Revenues: During the three months ended June 30, 2019, we realized $ 0 of revenues from our business. During the three months ended June 30, 2018, we realized $152,230 of revenues from our business. The change in revenues between the quarter ended June 30, 2019 and 2018 was $152,230 or 100%.

Cost of Revenues: Costs of revenues for the three months ended June 30, 2019 were $0, as compared to $0 for the three months ended June 30, 2018, a change of $0 or 0%.

Gross Profit: During the three months ended June 30, 2019, we realized a gross profit of $0, as compared to $152,230 for the three months ended June 30, 2018, a change of $152,230 or 100%.

Research and development expenses: During the three months ended June 30, 2019 we incurred $20,937 research and development expenses. During the three months ended June 30, 2018 we incurred $50,894 of research and development expenses, a decrease of $29,957 or 58.862% compared with the same period in 2018.

Professional Fees: During the three months ended June 30, 2019, we incurred $37,917 professional expenses, which increased by $7,591 or 25.03% from $30,326 for the three months ended June 30, 2018.

Officers Salary: During the three months ended June 30, 2019, officers’ salary expenses increased to $148,050 or 21.59% from $121,762 for the three months ended June 30, 2018. The increase in officer’s salary expenses was attributable to an increase in officer’s salary.

General and Administrative Expense: General and administrative expenses increased by $22,892 or 23.05% to $122,186 for the three months ended June 30, 2019 from $99,294 for the three months ended June 30, 2018. Our general and administrative expenses for the three months ended June 30, 2019 consisted of consulting fees of $5,787 and other general and administrative expenses (which includes expenses such as Auto, Business Development, SEC Filing, Investor Relations, General Office) of $55,062, Travel of $12,157 and office salary of $49,180, for a total of $140,145. Our general and administrative expenses for the three months ended June 30, 2018 consisted of consulting fees of $7,500 and other general and administrative expenses (which includes expenses such as Auto, Business Development, SEC Filing, Investor Relations, General Office, warrant Compensation) of $45,319, Travel of $8,390 and office salary of $38,085, for a total of $99,294. The primary reason for the increase in comparing the three months ended June 30, 2019 to the corresponding period for 2018 was mainly due to general business expenses.

Rent – Related Party: During the three months ended June 30, 2019, rent- related party expense increased to $6,153 or 113.65 % from $2,880 for the three months ended June 30, 2018. The rent-related party expense was attributable to the signing on January 23, 2017 the Company signed an eight year property lease with the Company’s President.

Interest Expense: Interest expense increase by $15,107 to $70,695 for the three month period ended June 30, 2019 from $55,588 for the three month period ended June 30, 2018. The increase was primarily due to interest on the loans.

Interest Income: Interest income increased by $3,442 to $3,442 for the three month period ended June 30, 2019 from $0 for the three month period ended June 30, 2018. The increase was primarily due to interest on bank accounts.

Net Loss: Net loss increased by $213,907, or 113.42 %, to a net loss of $402,497 for the three month period ended June 30, 2019 from a net loss of $188,590 for the three month period ended June 30, 2018. This increase in net loss was driven primarily by increases in general and administrative expenses and a decrease in revenues.

Six months ended June 30, 2019 compared to the Six Months Ended June 30, 2018

Our revenue, operating expenses, and net loss from operations for the six month period ended June 30, 2019 as compared to the six month period ended June 30, 2018, were as follows – some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:

|  | Six Months Ended June 30, 2019 Increase (Decrease) 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| NET REVENUES | $- | $260,859 | (260,859) | -100.00% |
| OPERATING EXPENSES: |  |  |  |  |
| General and Administrative | 240,153 | 280,948 | (40,795) | -14.52% |
| Professional Fees | 188,228 | 48,176 | 140,052 | 290.71% |
| Officer's Salary | 266,205 | 234,438 | 31,767 | 13.55% |
| Rent - Related Party | 9,426 | 5,760 | 3,666 | 63.65% |
| Research and Development | 43,241 | 71,021 | (27,780) | -39.12% |
| Total operating expenses | 747,253 | 640,343 | 106,910 | 16.70% |
| Loss from operations | (747,253) | (379,484) | (367,769) | 96.91% |
| Gain on forgiveness of debt | - | 19,924 | (19,924) | 100.00% |
| Interest expense | (137,615) | (107,959) | (29,656) | 27.47% |
| Interest income | 4,625 | - | 4,625 | 100.00% |
| Net Loss | $(880,243) | $(467,519) | (412,724) | 88.28% |

Net Revenues: During the six months ended June 30, 2019, we realized $ 0 of revenues from our business. During the six months ended June 30, 2018, we realized $260,859 of revenues from our business. The change in revenues between the quarter ended June 30, 2019 and 2018 was $260,859 or 100%.

Cost of Revenues: Costs of revenues for the six months ended June 30, 2019 were $0, as compared to $0 for the six months ended June 30, 2018, a change of $0 or 0%.

Gross Profit: During the six months ended June 30, 2019, we realized a gross profit of $0, as compared to $260,859 for the six months ended June 30, 2018, a change of $260,859 or 100%.

Research and development expenses: During the six months ended June 30, 2019 we incurred $43,241 research and development expenses. During the six months ended June 30, 2018 we incurred $71,021 of research and development expenses, a decrease of $27,780 or 39.12% compared with the same period in 2018.

Professional Fees: During the six months ended June 30, 2019, we incurred $188,228 professional expenses, which increased by $140,052 or 290.71% from $48,176 for the six months ended June 30, 2018.

Officers Salary: During the six months ended June 30, 2019, officers’ salary expenses increased to $266,205 or 13.55% from $234,438 for the six months ended June 30, 2018. The increase in officer’s salary expenses was attributable to an increase in officer’s salary.

General and Administrative Expense: General and administrative expenses decreased by $40,795 or 14.52% to $240,153 for the six months ended June 30, 2019 from $280,948 for the six months ended June 30, 2018. Our general and administrative expenses for the six months ended June 30, 2019 consisted of consulting fees of $5,787 and other general and administrative expenses (which includes expenses such as Auto, Business Development, SEC Filing, Investor Relations, General Office) of $126,149, Travel of $14,765 and office salary of $93,452, for a total of $240,153. Our general and administrative expenses for the six months ended June 30, 2018 consisted of consulting fees of $11,188 and other general and administrative expenses (which includes expenses such as Auto, Business Development, SEC Filing, Investor Relations, General Office, warrant Compensation) of $193,468, Travel of $9,208 and office salary of $67,084, for a total of $280,948. The primary reason for the decrease in comparing the six months ended June 30, 2019 to the corresponding period for 2018 was mainly due to general business expenses and warrant compensation.

Rent – Related Party: During the six months ended June 30, 2019, rent- related party expense increased to $9,426 or 63.65 % from $5,760 for the six months ended June 30, 2018. The rent-related party expense was attributable to the signing on January 23, 2017 the Company signed an eight year property lease with the Company’s President.

Interest Expense: Interest expense increase by $29,656 to $137,615 for the six month period ended June 30, 2019 from $107,959 for the six month period ended June 30, 2018. The increase was primarily due to interest on the loans.

Interest Income: Interest income increased by $4,625 to $4,625 for the six month period ended June 30, 2019 from $0 for the six month period ended June 30, 2018. The increase was primarily due to interest on bank accounts.

Net Loss: Net loss increased by $412,724, or 88.28 %, to a net loss of $880,243 for the six month period ended June 30, 2019 from a net loss of $467,519 for the six month period ended June 30, 2018. This increase in net loss was driven primarily by increases in professional fees and a decrease in revenues.

### Capital Resources and Liquidity

Our financial statements have been presented on the basis that we have a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As presented in the financial statements, we incurred a net loss of $880,243 during the six months ended June 30, 2019, and losses are expected to continue in the near term. The accumulated deficit is $4,067,265 at June 30, 2019. Refer to Note 2 for our discussion of stockholder deficit. We have been funding our operations through private loans and the sale of common stock in private placement transactions. Refer to Note 5 and Note 7 in the financial statements for our discussion of notes payable and shares issued, respectively. Our cash resources are insufficient to meet our planned business objectives without additional financing. These and other factors raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of our company to continue as a going concern.

Management anticipates that significant additional expenditures will be necessary to develop and expand our business before significant positive operating cash flows can be achieved. Our ability to continue as a going concern is dependent upon our ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. At June 30, 2019, we had $674,228 of cash on hand. These funds are insufficient to complete our business plan and as a consequence, we will need to seek additional funds, primarily through the issuance of debt or equity securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in the case of equity financing.

Management has undertaken steps as part of a plan to improve operations with the goal of sustaining our operations for the next twelve months and beyond. These steps include (a) raising additional capital and/or obtaining financing; (b) controlling overhead and expenses; and (c) executing material sales or research contracts. There can be no assurance that the Company can successfully accomplish these steps and it is uncertain that the Company will achieve a profitable level of operations and obtain additional financing. There can be no assurance that any additional financing will be available to the Company on satisfactory terms and conditions, if at all. As of the date of this Report, we have not entered into any formal agreements regarding the above.

In the event the Company is unable to continue as a going concern, the Company may elect or be required to seek protection from its creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy. To date, management has not considered this alternative, nor does management view it as a likely occurrence.

Cash, total current assets, total assets, total current liabilities and total liabilities as of June 30, 2019 as compared to December 31, 2018, were as follows:

|  | June 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Cash | $674,228 | $13,697 |
| Prepaid expenses | $35,245 | $6,858 |
| Total current assets | $709,473 | $20,555 |
| Total assets | $1,276,033 | $71,383 |
| Total current liabilities | $4,696,189 | $4,530,606 |
| Total liabilities | $5,343,298 | $4,530,606 |

At June 30, 2019, we had a working capital deficit of $3,986,716 compared to a working capital deficit of $4,510,051 at December 31, 2018. Current liabilities increased to $4,696,189 at June 30, 2019 from $4,530,606 at December 31, 2018, primarily as a result of primarily as a result of accounts payable, note payable and accrued compensation.

For the six months ended June 30, 2019, net cash used in operations of $455,469 was the result of a net loss of $880,243 offset by offset by depreciation expense of $13,403, warrants cancellation of $19,915, imputed interest on related party loans of $10,457, increase in prepaid expenses of $28,387 and decrease in operating lease right of useof $30,433, an increase of accrued expenses and other payables-related party of $373,469, an increase in accounts payable of $73,420 and a decrease in operating lease liabilities of $28,106. For the six months ended June 30, 2018, net cash used in operations of $141,156 was the result of a net loss of $467,519 offset by depreciation expense of $13,035, gain on forgiveness of debt of $19,924, imputed interest on related party loans of $4,771, warrants issued to consultants of $72,575, increase in accounts receivable of $88,128, an increase of accrued expenses and other payables-related party of $303,985 and an increase in accounts payable of $40,049.

Net cash used in our investing activities were $0 and $7,559 for the six months ended June 30, 2019 and June 30, 2018, respectively. Our investing activities for the six months ended June 30, 2018 are attributable to purchases of fixed assets.

Our financing activities resulted in a cash inflow of $1,116,000 for the six months ended June 30, 2019, which is represented by $1,000,000 proceeds from issuance of common stock, $4,000 loan repayment and $120,000 proceeds from shareholder note payable. Our financing activities resulted in a cash inflow of $165,000 for the six months ended June 30, 2018, which is represented by $165,000 proceeds from note payable – related party.

### Critical Accounting Policies

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2018, for disclosures regarding the Company's critical accounting policies and estimates, as well as updates further disclosed in our interim financial statements as described in this Form 10-Q.

### Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, *Leases*. The new standard increases transparency and comparability most significantly by requiring the recognition by lessees of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases longer than 12 months. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The Company adopted the new lease guidance effective January 1, 2019 using the modified retrospective transition approach, applying the new standard to all of its leases existing at the date of initial application which is the effective date of adoption. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. We elected the package of practical expedients which permits us to not reassess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases, and (3) any initial direct costs for any existing leases as of the effective date. We did not elect the hindsight practical expedient which permits entities to use hindsight in determining the lease term and assessing impairment. The adoption of the lease standard did not change our previously reported consolidated statements of operations and did not result in a cumulative catch-up adjustment to opening equity. As a result, the Company has recorded Right-to-use assets and corresponding Lease obligations as more fully discussed in Note 4.

In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The guidance permits entities to reclassify tax effects stranded in Accumulated Other Comprehensive Income as a result of tax reform to retained earnings. This new guidance is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted in annual and interim periods and can be applied retrospectively or in the period of adoption. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. The amendment provides guidance on accounting for the impact of the Tax Cuts and Jobs Act (the “Tax Act”) and allows entities to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard is effective upon issuance. The Tax Act has several significant changes that impact all taxpayers, including a transition tax, which is a one-time tax charge on accumulated, undistributed foreign earnings. The calculation of accumulated foreign earnings requires an analysis of each foreign entity’s financial results going back to 1986. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify certain disclosure requirements of fair value measurements and are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.

Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11on its financial statements.

All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as “special purpose entities” (SPEs).

## Controls and procedures

As filed, 3,479 characters.

#### Evaluation of Disclosure Controls and Procedures

As of the end of our fiscal quarter ended June 30, 2019, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon those evaluations, management concluded that our disclosure controls and procedures were not effective as of June 30, 2019, to cause the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods prescribed by SEC, and that such information is accumulated and communicated to management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Going forward from this filing, the Company intends to work on re-establishing and maintaining disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

### Changes in Internal Control over Financial Reporting

During the quarter covered by this Report, there were no changes in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. Although we continue to educate our management personnel to increase to increase its ability to comply with the disclosure requirements and financial reporting controls and management oversight of accounting and reporting functions in the future, as we stated in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, we do not expect to remediate the weaknesses in our internal controls over financial reporting until the time when we start to commercialize a recombinant fiber and, therefore may have sufficient cash flow to carry out our remediation plans.

## Risk factors

As filed, 173 characters.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this item.

Filed Aug 12, 2019.
Source: SEC EDGAR, the filing index for accession 0001654954-19-009271. Last ingested by Listed: Oct 24, 2026, 15:09 ET. No prices; not investment advice.
